1️⃣
💊 Mycophenolate mofetil (MMF) remains a backbone immunosuppressant in lupus nephritis, ILD, and more.
But in 2025, its story has evolved — from better combos to smarter uses.
Let’s unpack the latest. 👇
2️⃣
🔬 How it works
MMF blocks inosine monophosphate dehydrogenase (IMPDH) → shuts down guanosine synthesis.
This hits T & B cells hard (they rely on de novo purine synthesis).
🛑 Autoimmunity off, immunity preserved… mostly.
3️⃣
🧠 What’s new mechanistically?
MMF not only suppresses lymphocytes but also tips the scale toward regulatory T cells (Tregs).
📉 CD4+, CD8+, B cells ↓
📈 Foxp3+ Tregs ↑
A quiet immune recalibration, not just brute-force suppression.
4️⃣
📚 Updated Guidelines (ACR & KDIGO 2024–25)
✅ MMF now first-line in lupus nephritis (esp. Class III–V)
✅ Often combined with steroids + belimumab or voclosporin
✅ Pediatric SLE? MMF is no longer off-label — it’s endorsed.
🧠 Treat early. Combine smartly.
5️⃣
🏥 Clinical Uses (beyond LN)
• Systemic sclerosis-ILD
• ANCA vasculitis (maintenance)
• Autoimmune hepatitis (select cases)
• Uveitis, myositis, Sjögren’s (off-label)
Versatile, especially when fertility or renal preservation matters.
6️⃣
🧪 MMF vs AZA — 2025 Data
A recent RCT confirms it:
MMF > Azathioprine in preventing SLE flares during maintenance.
🛡️ Better disease control, same safety profile.
Evidence is stacking up.
7️⃣
🚨 Side Effects to Watch
• GI: nausea, diarrhea
• Cytopenias
• Opportunistic infections (CMV, BK)
• Rare: hepatotoxicity
🔄 Switch to enteric-coated MPA if GI issues persist.
Stay alert, not afraid.
8️⃣
👶 Pregnancy & Fertility
🚫 MMF is teratogenic — linked to miscarriage and malformations.
💡 Stop 6 weeks before conception.
✅ Use azathioprine or HCQ in pregnancy.
Fertility-sparing, but not pregnancy-safe.
9️⃣
🧠 Monitoring Tips
No routine MPA levels. Focus on:
• CBC, LFTs, renal function
• Infection screening (CMV, TB, BK)
• Adherence
🧬 And don’t forget: no live vaccines during treatment.
🔄 Recheck before vaccines or surgery.
📈 Emerging Uses (2025)
• 🫁 Systemic sclerosis skin fibrosis — modest mRSS improvement in meta-analyses
• 🧠 AI-guided lupus nephritis pathology scoring now helps personalize MMF dosing
• 🧴 Liver transplant patients switching from CNIs to MMF show renal rescue!
🧬 It’s not just for lupus anymore.
1️⃣1️⃣
🧠 Pro Tips for 2025 Practice
• MMF + belimumab = synergy
• Splitting dose improves GI tolerance
• Expect immunoglobulin dip → watch for infections
• Counsel early on fertility & contraception
🎯 Use it wisely. It rewards experience.
1️⃣2️⃣
💡 MMF in 2025 is not just about suppression — it’s about precision, preservation, and personalization.
From lupus kidneys to scleroderma lungs, MMF continues to deliver.
#RheumTwitter #NEETPG
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Gout is the most common inflammatory arthritis, yet nearly 80% of patients are suboptimally managed, leading to preventable flares, tophi, and joint damage.
Forget the old myths of “kings and diet.”
Here is the modern, evidence-based approach to gout management, aligned with ACR guidelines, for the busy clinician. 🧵
MYTH: Gout is purely a “lifestyle disease” fixed by diet.
FACT: Diet typically alters serum urate by ~1 mg/dL at most.
Gout is primarily a genetically determined disorder of renal urate under-excretion.
You cannot “diet away” established gout. Medication is usually required.
Tweet 3 - The Goal (Treat-to-Target)
The goal of therapy isn’t just stopping flares - it’s dissolving monosodium urate crystals.
That requires a Treat-to-Target strategy:
• Target serum urate < 6.0 mg/dL for all gout patients
• If tophi are present: < 5.0 mg/dL for faster crystal clearance
The Clinical Approach to a Positive Antinuclear Antibody (ANA):
A positive ANA is one of the most common consults in Internal Medicine, yet it is widely misunderstood.
Positive ANA ≠ Lupus.
It causes significant patient anxiety and unnecessary referrals.
Here is the evidence-based approach to interpreting a positive ANA for the busy clinician. 🧵
#MedEd #Rheumatology #MedTwitter @DrAkhilX @IhabFathiSulima #InternalMedicine #Lupus #MedicalEducation
First, understand the pre-test probability.
ANA is not a screening test for fatigue or nonspecific pain.
Why? Up to 20–30% of the healthy population has a positive ANA at 1:40 titer. Even at 1:160, ~5% of healthy individuals are positive.
#Diagnostics #ClinicalPearls #PrimaryCare
The Titer is the key to specificity.
• 1:40 to 1:80: Low positive. Low clinical significance in isolation.
• 1:160: Intermediate.
• ≥ 1:320: High positive. Higher specificity for autoimmune disease, but still requires clinical correlation.
Treat the patient, not the number.
Ozempic vs Mounjaro — the REAL 2025 comparison.
🧵Thread🔥👇
Everyone is talking about weight-loss drugs. But the REAL showdown is Ozempic vs Mounjaro — and the winner is clear.
Ozempic and Mounjaro should be prescribed ONLY after medical assessment — never self-started.
🧵 5 Lab Traps That Delay Lupus Diagnosis (with one example)
I’ve seen lupus hide behind “normal” labs more times than I can count.
Here are 5 lab traps that delay the diagnosis — with one real case that’ll stick with you. 🧵👇
@DrAkhilX @IhabFathiSulima @DrNikhilMD @Janetbirdope @DurgaPrasannaM1 #MedTwitter #RheumTwitter #Autoimmunity
1️⃣ “ANA is negative, so it’s not lupus.”
Wrong.
Early SLE can have low-titer or even transiently negative ANA.
🧠 If your gut says lupus, repeat it after a few weeks.
2️⃣ “CRP is high, so it must be infection.”
Not always.
Lupus flares often have normal CRP.
High CRP just means: check if there’s serositis, arthritis… or yes, infection.